When FDA Requires Pediatric Studies for New Cancer Drug Submissions: New Draft Guidance

Beginning 18 August 2020, biopharma companies will begin submitting pediatric assessments of certain molecularly targeted oncology drugs for which new drug applications (NDAs) and biologics license applications (BLAs) are expected to be submitted to the US Food and Drug Administration (FDA).